Literature DB >> 3888489

Clinical pharmacokinetics of prazosin--1985.

J Vincent, P A Meredith, J L Reid, H L Elliott, P C Rubin.   

Abstract

Prazosin is a selective alpha 1-adrenoceptor antagonist which is useful alone or in combination for the treatment of hypertension and heart failure. Unlike many other antihypertensive drugs, the action of prazosin appears to be closely related to its concentration in plasma or whole blood. Prazosin is variably absorbed, is subject to first-pass metabolism, and is eliminated almost entirely as metabolites of much lower hypotensive activity than the parent drug. Prazosin is highly bound to plasma and tissue proteins. The influences of renal, hepatic and cardiac disease on the disposition of prazosin are reviewed, as are the effects of pregnancy and ageing. The optimum use of prazosin in clinical practice depends on an understanding of the pharmacokinetic properties of the drug.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3888489     DOI: 10.2165/00003088-198510020-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  49 in total

1.  Some alterations in the pattern of drug metabolism aociated with pegnancy, oral contraceptives, and the newly-born.

Authors:  J S Crawford; S Rudofsky
Journal:  Br J Anaesth       Date:  1966-06       Impact factor: 9.166

2.  Prazosin: the first-dose phenomenon.

Authors:  R M Graham; I R Thornell; J M Gain; C Bagnoli; H F Oates; G S Stokes
Journal:  Br Med J       Date:  1976-11-27

3.  Acute hypotensive response to nifedipine added to prazosin in treatment of hypertension.

Authors:  L D Jee; L H Opie
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-19

Review 4.  The modelling of drug response.

Authors:  B Whiting; A W Kelman
Journal:  Clin Sci (Lond)       Date:  1980-11       Impact factor: 6.124

5.  Prazosin protein binding in health and disease.

Authors:  P Rubin; T Blaschke
Journal:  Br J Clin Pharmacol       Date:  1980-02       Impact factor: 4.335

6.  Influence of congestive heart failure on prazosin kinetics.

Authors:  P Jaillon; P Rubin; Y G Yee; R Ball; R Kates; D Harrison; T Blaschke
Journal:  Clin Pharmacol Ther       Date:  1979-06       Impact factor: 6.875

7.  Effect of low doses of heparin on the plasma binding of phenytoin and prazosin in normal man.

Authors:  P Schulz; K M Giacomini; S Luttrell; K Turner-Tamiyasu; T F Blaschke
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Combined use of prazosin and beta-blockers in hypertension.

Authors:  G S Stokes; J Raftos; R G Lewis; A S Mitchell; D Jeremy; G W Frost; I R Thornell
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

9.  The metabolic fate of prazosin.

Authors:  J A Taylor; T M Twomey; M S von Wittenau
Journal:  Xenobiotica       Date:  1977-06       Impact factor: 1.908

Review 10.  Clinical pharmacokinetics of prazosin.

Authors:  P Jaillon
Journal:  Clin Pharmacokinet       Date:  1980 Jul-Aug       Impact factor: 6.447

View more
  12 in total

Review 1.  The treatment of hypertension in pregnancy. Clinical pharmacokinetic considerations.

Authors:  C Knott
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

Review 2.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 3.  Pharmacokinetic-pharmacodynamic relationships of alpha-adrenoceptor antagonists.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

4.  The pharmacokinetics of doxazosin in elderly normotensives.

Authors:  J Vincent; P A Meredith; H L Elliott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

5.  Prazosin concentration monitoring in the treatment of prostatic adenoma.

Authors:  S Dutkiewicz; M Filipek
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

6.  Effect of an alpha(1)-adrenergic blocker on plasticity elicited by motor training.

Authors:  L Sawaki; K J Werhahn; R Barco; L Kopylev; L G Cohen
Journal:  Exp Brain Res       Date:  2002-12-13       Impact factor: 1.972

Review 7.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

8.  Synthesis of poly(hydroxypropylglutamine-prazosin carbamate) and release studies.

Authors:  X L Li; N W Adams; D B Bennett; J Feijen; S W Kim
Journal:  Pharm Res       Date:  1991-04       Impact factor: 4.200

Review 9.  Clinical pharmacokinetics of vasodilators. Part II.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

10.  Nifedipine-prazosin interaction in patients with essential hypertension.

Authors:  I Kiss; C Farsang
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.